Table 1. Descriptive data of the study participants.
| Descriptive | NC | PD | P-value |
|---|---|---|---|
| N | 32 | 33 | — |
| Age at MRI (years) | 62.9 (10.0) (40–82) | 64.9 (7.0) (48–74) | 0.533a |
| Gender (male/female (%)) | 44/56 | 64/36 | 0.108b |
| Education (years) | 13.5 (2.8) (8–18) | 13.1 (3.3) (8–19) | 0.663a |
| MMSE score | 29.3 (0.7) (28–30) | 28.6 (1.6) (22–30) | 0.019*a |
| Duration of motor symptoms (years) | — | 2.7 (1.5) (1–6) | — |
| Hoehn and Yahr stage (median) | — | 1.5 (1–2.5) | — |
| UPDRS part III motor score | — | 14.4 (6.5) (3–31) | — |
| Levodopa equivalent doses | — | 392.2 (249.4) (0–924) | — |
| Geriatric depression scale | — | 1.2 (1.4) (0–6) | — |
| N | 23 | 31 | — |
| Aβ38 (ng/l) | — | 1878.6 (775.1) (819.1–4550.9) | — |
| Aβ40 (ng/l) | — | 5125.4 (1772.9) (2212.2–10512.3) | — |
| Aβ42 (ng/l) | 1007.6 (187.2) (692.0–1290.0) | 943.0 (154.6) (707.0–1280.0) | — |
| T-tau (ng/l) | 374.9 (188.1) (154.0–893.0) | 271.1 (132.8) (119.0–734.0) | — |
| P-tau (ng/l) | 55.7 (18.3) (37.0–110.0) | 45.6 (25.3) (25.0–155.0) | — |
| N | — | 24 | — |
| T-α.syn (ng/l) | — | 282.6 (74.4) (174.3–476.2) | — |
Abbreviations: Aβ, amyloid-β; MRI, magnetic resonance imaging; MMSE, Mini-Mental State Examination; NC, normal controls; PD, Parkinson’s disease patients; P-tau, phosphorylated tau; T-tau, total tau; t-α-syn, total α-synuclein; UPDRS, unified Parkinson’s disease rating scale.
Values are presented as mean (s.d.) (range) unless otherwise stated.
a
Mann–Whitney test.
b
Pearson χ 2-test.
*Significant P⩽0.05.